RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--TransEnterix, Inc. (NYSE MKT:TRXC), a medical device company that is pioneering the use of robotics and flexible instruments to improve minimally invasive surgery, today announced its operating and financial results for the second quarter 2015. Operating Highlights Completed Good Laboratory Practices (GLP) Studies using the SurgiBot™ System in April 2015 SurgiBot System FDA 510(k) Application Submitted June 1, 2015 Completed underwritten equity off
| < Prev | Next > |
|---|
